Key facts
- This page summarizes Shalini Sharp's Form 3 filing for Iambic Therapeutics, Inc..
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Oct 2026, 18:48.
Shalini Sharp - 14 Oct 2026 Form 3 Insider Report for Iambic Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Oct 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 14 Oct 2026, 18:48:12 UTC
- Prior SEC filing
- 30 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sunny Chang, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Shalini Sharp filed Form 3 for Iambic Therapeutics, Inc. on 14 Oct 2026.
Change
- Previous filing in this sequence was filed on 30 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001377202
Primary reporting owner
Sharp Shalini
- Relationship
- Director
- Address
- C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO
- Signature
- /s/ Sunny Chang, by power of attorney
- Signature date
- 14 Oct 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 14 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 66,556
- Exercise price
- $8.73
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Twenty-five percent of the shares subject to the option vested on September 25, 2026 and 1/48th of the shares vest monthly thereafter.
SEC remarks
Exhibit 24.1 - Power of Attorney